Dr. Willmar Schwabe Gmbh & Co.

Willmar Schwabe Gmbh & Co.

Firma Willmar Schwabe

Cermol S.a.

Iso Arzneiminel Gmbh & Co. Kg

William Schwabe Gmbh & Co.

Willman - Schwabe Gmbh & Co.

Dr. Willmar Schwabe Gmbh & Co. Kg

Shyam Sunder Chatterjee

Klaus Klessing

Hermann E Jaggy

Hermann Hauer

Bernard L Gabard

Clemens Erdelmeier

Egon Koch

Michael Noldner

Danielle Straumann

Carlos Sunkel Letelier

Hermann Ernst Jaggy

Julio Alvarez-Builla Gomez

Michael Nöldner

Dieter Marme

Jos&eacute; M Minguez Ortega

Benard L Gabard

Pierre Statkow

Michael N Oldner

Miguel Fau De Casa-Juana Munoz

Christoph Sch&auml;chtele

Michael N&ouml;ldner

Karl SCHÖTZ

The use of extracts fromspecies or plant parts thereof, particularly fromandfor the prophylaxis or treatment of disease-related behavioral changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these extracts are described.

[object Object]

Pyridyl compounds and pharmaceutical compositions containing them

Stable hyperforin salts, method for producing same and their use in the treatment of alzheimer's disease

The invention relates to the use of hyperforin and hyperforin-containing extracts of,(St. John's wort) in the treatment and prophylaxis of dementia diseases, including Alzheimer's disease, as well as the use of hyperforin and hyperforin-containing extracts for the preparation of a medicament for the treatment and prophylaxis of such dementia diseases.

Use of hyperforin and hyperforin-containing extracts in the treatment of dementia diseases

The invention relates to a novel 2H-1-pyran-2-ones of general formula (I),

Pyranones, method for the production and use thereof

Pharmaceutical preparations containing bilobalide for the treatment of

Preparations of Crataegus species, pharmaceutical compositions and their

Benzopyranones, processes for their preparation and their use

Benzopyranones, a method for producing them and uses therefor

Amino acid esters, process for the preparation thereof and use thereof

Medicaments containing bilobalide which can be used to control nervous diseases are described.

Pharmaceutical compositions containing bilobalide for the treatment of

The present invention provides 5-arylalkyl-4-alkoxy-2(5H)-furanones of the formula: ##STR1## wherein the oxygen atoms on C-5 and C-.alpha., relative to one another, are in the threo-position, with the exclusion of those compounds of the formula (I) wherein R.sup.2 is H or CH.sub.3 when n=0 or 2, R.sup.o =H, R.sup.1 =CH.sub.3, R.sup.3 =H and R.sup.4 =H. The present invention also provides processes for their preparation, as well as new 3-alkoxy-5-(subst.)-phenyl-2(E), 4(E)-pentadienoates as reactive intermediates for the preparation of the new furanone derivatives. The new furanone derivatives of the threo series are active as anticonvulsives/anti-epileptics. Therefore, the present invention also provides medicaments which contain these new furanone derivatives, as well as known furanones, the anticonvulsive/anti-epileptic effectiveness of which has been found for the first time.

5-arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and processes for

1.4;3.6-Dianhydrohexitol nitrates substituted by purine bases, namely, adenyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ia as well as theophyllinyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ib, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and, independently of one another signify

1.4;3.6-Dianhydrohexitol nitrates substituted by purine bases, and

Medicaments containing bilobalid which can be used to control nervous diseases are described.

Pharmaceutical compositions containing bilobalid for the treatment of

Alkylaminodesoxy-1.4;3.6-dianhydrohexitol nitrates substituted by purine bases of the general formula I, ##STR1## wherein R.sup.1 signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms, X a straight-chained or branched alkyl or hydroxyalkyl group with 1 to 7 C-atoms, Y a 1,3-dialkylxanthin-7-yl or a 3,7-dialkylxanthin-1-yl group, each with straight or branched-chained alkyl groups with 1 to 5 C-atoms, or an adenin-9-yl group, as well as their physiologically acceptable acid-addition salts. Process for the preparation of said compounds and pharmaceutical compositions containing said compounds.

Alkylaminodesoxy-1.4;3.6-dianhydrohexitol nitrates substituted by purine

Growing community of inventors

Karlsruhe, Germany

Shyam Sunder Chatterjee